Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2010 / Cilt: 18 - Sayı: 4

Kalp cerrahisi sonrası aşırı kanamaya karşın kurtarıcı tedavi olarak rekombinant faktör VIIa kullanımı

Use of recombinant factor VIIa as a rescue therapy for excessive bleeding after cardiac surgery

Pages
324–326
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

No postoperative thromboembolic event was detected, and no clinical problem was observed in one-year follow-up.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Excessive bleeding after cardiac surgery is associated with increased mortality and morbidity.
📊
Key Findings & Data:In this article, we report a 74-year-old male patient with atrial fibrillation who suffered from dyspnea for two months.
💡
Conclusion & Impact:No postoperative thromboembolic event was detected, and no clinical problem was observed in one-year follow-up.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Excessive bleeding after cardiac surgery is associated with increased mortality and morbidity. Nonsurgical management includes regulation of activated clotting time, nonred cell (fresh frozen plasma, platelets, cryoprecipitate) blood product support, desmopressin, antifibrinolytics and activated recombinant factor VIIa. In this article, we report a 74-year-old male patient with atrial fibrillation who suffered from dyspnea for two months. There were no coagulation abnormalities preoperatively. The patient underwent aortic and mitral valve replacement with mechanical prosthesis, tricuspid valve annuloplasty and left atrial radiofrequency ablation for the treatment of atrial fibrillation. Recombinant factor VIIa was used for excessive postoperative bleeding, the bleeding decreased rapidly and ceased at the 4th hour of the medication. No postoperative thromboembolic event was detected, and no clinical problem was observed in one-year follow-up.

Özet

Kalp cerrahisi sonrası aşırı kanama artmış mortalite ve morbiditeye neden olmaktadır. Bu patolojinin cerrahi dışı tedavisinde; aktive pıhtılaşma zamanının regülasyonu, taze donmuş plazma, trombosit ve kriyopresipitat gibi eritrosit içermeyen kan ürünleri desteği, desmopressin, antifibrinolitikler ve aktive rekombinant faktör VIIa yer almaktadır. Bu yazıda iki aydır nefes darlığı yakınması olan atriyal fibrilasyonlu 74 yaşında erkek hasta sunuldu. Ameliyat öncesinde koagülasyon bozukluğu yoktu. Hastaya aort ve mitral mekanik kapak değişimi, triküspit kapak anüloplastisi ve atriyal fibrilasyon tedavisi için sol atriyal radyofrekans ablasyon işlemi yapıldı. Ameliyat sonrası aşırı kanama geliştiği için rekombinant faktör VIIa kullanıldı ve uygulama sonrasında kanama hızlı bir şekilde azalarak tedavinin 4. saatinde tamamen kesildi. Ameliyat sonrası bir yıllık takip süresince tromboembolik olay saptanmadı ve klinik sorun gözlenmedi.

🔖

Cite This Article

TORAMAN, F., ALHAN, C., RATİP, S., ŞENAY, Ş., KARABULUT, H. (2022). Kalp cerrahisi sonrası aşırı kanamaya karşın kurtarıcı tedavi olarak rekombinant faktör VIIa kullanımı. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 18 - Sayı: 4, 324–326. https://ajindex.com/articles/424962

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Nuttall GA, Oliver WC, Santrach PJ, Bryant S, Dearani JA, Schaff HV, et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 2001;94:773 81
  2. Levi M, Peters M, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005;33:883-90
  3. Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John K, et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg 2007; 83:707-14
  4. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996;111:1037-46
  5. Hedner U, Glazer S, Pingel K, Alberts KA, Blombäck M, Schulman S, et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988;2:1193
  6. O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-8.